Advertisement

Advertisement

LYRA Stock Latest News

Lyra Therapeutics Withdraws Nasdaq Appeal, Faces Imminent Delisting

Company AnnouncementsLyra Therapeutics Withdraws Nasdaq Appeal, Faces Imminent Delisting

LYRA Earnings this Week: How Will it Perform?

PremiumPre-Earnings

LYRA Earnings this Week: How Will it Perform?

17d ago

Lyra Therapeutics Faces Nasdaq Delisting After Becoming Shell

PremiumCompany Announcements

Lyra Therapeutics Faces Nasdaq Delisting After Becoming Shell

2M ago

Lyra Therapeutics common stock to be delisted by Nasdaq

PremiumThe Fly

Lyra Therapeutics common stock to be delisted by Nasdaq

2M ago

One new option listing and option delistings on January 20th

PremiumThe Fly

One new option listing and option delistings on January 20th

2M ago

Morning News Wrap-Up: Monday’s Biggest Stock Market Stories!

PremiumMarket NewsMorning News Wrap-Up: Monday’s Biggest Stock Market Stories!

2M ago

Why Is Lyra Therapeutics Stock (LYRA) Down Today?

Market News

Why Is Lyra Therapeutics Stock (LYRA) Down Today?

2M ago

Lyra Therapeutics Halts LYR-210, Cuts Workforce, Explores Options

Company Announcements

Lyra Therapeutics Halts LYR-210, Cuts Workforce, Explores Options

2M ago

Lyra Therapeutics suspends further development of LYR-210

PremiumThe Fly

Lyra Therapeutics suspends further development of LYR-210

2M ago

Cautious Hold Rating for Lyra Therapeutics Amid Strategic Focus and Financial Challenges

PremiumRatings

Cautious Hold Rating for Lyra Therapeutics Amid Strategic Focus and Financial Challenges

4M ago

Lyra Therapeutics Faces Financial Challenges Amid Clinical Setbacks

PremiumCompany Announcements

Lyra Therapeutics Faces Financial Challenges Amid Clinical Setbacks

4M ago

Lyra Therapeutics reports Q3 EPS ($3.38), consensus ($4.07)

PremiumThe Fly

Lyra Therapeutics reports Q3 EPS ($3.38), consensus ($4.07)

4M ago

LYRA Upcoming Earnings Report: What to Expect?

PremiumPre-EarningsLYRA Upcoming Earnings Report: What to Expect?

5M ago

Lyra Therapeutics announces clinical plan for LYR-210

The Fly

Lyra Therapeutics announces clinical plan for LYR-210

6M ago

Lyra Therapeutics Posts Corporate Presentation on LYR-210

Company Announcements

Lyra Therapeutics Posts Corporate Presentation on LYR-210

7M ago

Lyra Therapeutics Receives Nasdaq Deficiency Letter

PremiumCompany Announcements

Lyra Therapeutics Receives Nasdaq Deficiency Letter

7M ago

Cautious Hold Rating on Lyra Therapeutics Amid Uncertainty in LYR-210’s Development and Approval Prospects

PremiumRatings

Cautious Hold Rating on Lyra Therapeutics Amid Uncertainty in LYR-210’s Development and Approval Prospects

7M ago

Lyra Therapeutics Faces Manufacturing and Staffing Challenges Amid LYR-210 Production Shift

PremiumCompany Announcements

Lyra Therapeutics Faces Manufacturing and Staffing Challenges Amid LYR-210 Production Shift

7M ago

Lyra Therapeutics Reports Q2 2025 Financial Results

PremiumCompany Announcements

Lyra Therapeutics Reports Q2 2025 Financial Results

8M ago

Lyra Therapeutics reports Q2 EPS ($5.51), consensus ($4.78)

PremiumThe FlyLyra Therapeutics reports Q2 EPS ($5.51), consensus ($4.78)

8M ago

Is LYRA a Buy, Before Earnings?

Pre-Earnings

Is LYRA a Buy, Before Earnings?

8M ago

Lyra Therapeutics Announces Leadership Changes in August 2025

Company Announcements

Lyra Therapeutics Announces Leadership Changes in August 2025

8M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >